Discover. Innovate. Deliver.

BrainStorm is a leader in developing innovative autologous cellular therapies for highly debilitating neurodegenerative diseases. With a strong focus on defeating neurodegenerative diseases, BrainStorm utilizes their cutting-edge NurOwn® technology platform to produce commercial-ready MSC-NTF cells, which are at the forefront of a new class of autologous cellular therapeutics. This groundbreaking platform addresses the pressing medical needs of patients with limited treatment options, offering hope to those suffering from conditions like amyotrophic lateral sclerosis (ALS) and progressive multiple sclerosis (MS).

BrainStorm's dedication to advancing cellular therapeutics is evident in their completion of a phase 3 pivotal trial for ALS and a phase 2 study for progressive MS. Their autologous MSC-NTF cell therapy has received Fast Track designation from the U. S.

FDA, and has been granted Orphan Status by both the U. S. FDA and the European Medicines Agency (EMA).

With their headquarters in New York City, BrainStorm is committed to revolutionizing the treatment of neurodegenerative diseases and improving the lives of patients worldwide